Clinical trials have begun for the now-ubiquitous DNA-testing company 23andMe’s new cancer drug. The immuno-oncology antibody, named 23ME-000610, targets solid tumors and is part of a broader push towards immunotherapies in cancer. The first patient received their first dose of the drug in the […]
Webinar: Strategies to Overcome CAR-T Cell Resistance During Cell Therapy
CAR-T cell therapy has shown great potential in certain lymphoma and leukemia patients. However, resistance to the CAR-T cells in some patients limits the utility of the therapy. In a Sartorius Webinar, Dr. Dr. Adrian Bot, VP and Global Head of Translational Medicine and the Head of Research in […]
Insider Trading Charges Filed Against University of Chicago Professor
University of Chicago professor Daniel Catenacci, MD has been charged with insider trading regarding his actions during a phase 2 trial of the stomach cancer treatment bemarituzumab. Catenacci is accused of buying 8,743 shares of Five Prime Therapeutics, the company sponsoring the […]
Oncology Care Model Reduces Medicare Costs for Cancer Treatment
A study evaluating the benefits of the Oncology Care Model, an alternate payment model for Medicare beneficiaries with cancer, found the program offered tangible, if modest, payment reductions. The Centers for Medicare & Medicaid Services Launched the Oncology Care Model (OCM) in 2016 to help […]
Why Don’t Oncologists Order Molecular Testing?
Many oncologists do not order molecular testing for precision oncology treatment despite the established benefits. An article in JCO Precision Oncology examined the rationales behind these decisions. Around 78% said that they were unpersuaded of the relevance or clinical utility, and another 72% […]
Navigating the FDA Real-Time Oncology Review Process for Sponsors
Started in 2018, the FDA’s “Real-Time Oncology Review (ROTR)” project gives sponsors a head start on the application review process and poses additional challenges. The ROTR helps sponsors plan around anticipated FDA results immediately to begin preparing their full submission package […]
xCures Releases xDECIDE Platform to Personalize Cancer Care Using RWD
Released earlier this month, the xDECIDE platform helps doctors choose the optimal treatment strategy for cancer patients, according to a press release from xCures. The consolidated online platform uses real-world data (RWD), expert recommendations, and an advanced learning network to provide a […]
Are Mammograms After 75 Worth It?
Uncertainty is building regarding the value of mammograms for breast cancer screening after 75 years of age according to a study published in the journal Annals of Internal Medicine. The harms of overdiagnosis may outweigh the human and economic benefits of the relatively small number of breast […]
[JAMA Article] New Oncology Drugs Command High Price Tags Despite Lack of Improved Survival
In an article published in JAMA Internal Medicine, researchers assessed the costs of 44 new oncology drugs. Surprisingly, they found that an increasing number of patients were receiving drugs without clear overall survival data. “The investigators suggested that the increased spending on cancer […]
New Report Considers Use of Oncology RWE in Successful Submissions to the FDA
In a recent article published in Clinical Cancer Research, investigators analyzed successful submissions of oncology drugs to the Food and Drug Administration (FDA) that utilized real world evidence (RWE). The researchers identified elements criticized by the FDA, including confounding factors, and […]
